Recombinant DNA is DNA constructed by joining segments from separate DNA molecules through laboratory methods. The segments may originate from different organisms, from the same organism, or from chemically synthesized sequences; combining different species is not essential. Recombinant DNA technology encompasses the methods used to assemble, introduce, replicate, and study these constructs. It is a foundational tool of molecular biology, enabling researchers to isolate genetic sequences and produce particular biological products in host cells. (genome.gov)
Molecular principles
A recombinant construct commonly contains an insert, the sequence of interest, joined to a cloning vector, a DNA molecule that carries the insert into a host cell. Many vectors also support replication of the construct. An insert may contain a complete gene, a regulatory region, or a fragment with no protein-coding function. The resulting molecule is defined by its assembled DNA sequences, not by whether it produces a new protein. (ncbi.nlm.nih.gov)
Plasmids are widely used vectors because they can replicate separately from bacterial chromosomal DNA and are relatively easy to manipulate. A typical plasmid vector contains an origin supporting DNA replication, insertion sites, and a selectable marker. Other vector systems include bacteriophages and artificial chromosomes, whose suitability depends on the host, insert size, and experimental purpose. (ncbi.nlm.nih.gov)
Construction and identification
Classical construction uses restriction enzymes to cut DNA at particular recognition sequences. Some cuts generate complementary single-stranded overhangs, called cohesive or “sticky” ends, which allow fragments to associate through base pairing. DNA ligase then seals breaks in the DNA backbone, creating covalently joined molecules. Blunt-ended fragments can also be joined, and synthetic linkers can introduce useful restriction sites. (ncbi.nlm.nih.gov)
Assembly is not restricted to cutting and ligating at restriction sites. Gibson assembly, described in 2009, joins fragments with overlapping ends through the combined action of an exonuclease, DNA polymerase, and ligase. Such approaches permit seamless assembly of multiple fragments, including natural and synthetic genes and larger genetic constructs. (pubmed.ncbi.nlm.nih.gov)
In molecular cloning, recombinant molecules are introduced into host cells and propagated to obtain many copies. Bacteria, especially Escherichia coli, are common hosts. Selectable markers help distinguish cells carrying vectors from those without them. Selection alone does not establish that a vector contains the intended insert: candidate clones require further screening or characterization. Restriction analysis, gel electrophoresis, and DNA sequencing help identify and examine cloned DNA. (ncbi.nlm.nih.gov)
DNA propagation and gene expression
Copying a recombinant molecule and expressing its genes are distinct outcomes. A construct may replicate successfully while producing no detectable gene product. Production requires appropriate regulatory sequences and compatibility with the host’s gene-expression machinery. Expression constructs therefore link coding sequences to regulatory elements that enable the host to generate the intended RNA or protein. (pmc.ncbi.nlm.nih.gov)
For many genes from eukaryotes, complementary DNA (cDNA) provides a useful alternative to genomic DNA. It is synthesized from an RNA template by reverse transcriptase. When derived from mature messenger RNA, cDNA lacks the introns removed during RNA processing. Comparing cDNA with genomic clones also reveals how genes are organized and how their transcripts are processed. (ncbi.nlm.nih.gov)
Historical development
In 1972, Paul Berg’s laboratory constructed recombinant molecules combining DNA from simian virus 40 with bacteriophage-derived DNA carrying bacterial genetic sequences. This demonstrated that DNA from different sources could be assembled outside living cells. Berg received half of the 1980 Nobel Prize in Chemistry for fundamental studies of nucleic-acid biochemistry, particularly recombinant DNA. (pmc.ncbi.nlm.nih.gov)
In November 1973, Stanley Cohen, Annie Chang, Herbert Boyer, and Robert Helling published experiments showing that fragments from separate bacterial plasmids could be joined into biologically functional plasmids. These molecules replicated in E. coli and expressed antibiotic-resistance properties. The work established a practical connection between assembling DNA in vitro and propagating functional constructs in living hosts. (pubmed.ncbi.nlm.nih.gov)
Applications
Recombinant DNA allows individual genetic fragments to be isolated from complex mixtures, amplified, and investigated. Collections of cloned fragments form DNA libraries, which can represent genomic DNA or expressed RNA sequences through cDNA. These resources have supported studies of gene structure, regulation, and genome organization. Assembled constructs also allow researchers to examine how particular coding and regulatory sequences function together. (ncbi.nlm.nih.gov)
A major industrial application is the production of human proteins in engineered host cells. Insulin is an early example: scientists developed recombinant methods for producing human insulin in 1978, and the United States Food and Drug Administration approved Humulin on October 28, 1982. It was the first approved medical product derived from recombinant DNA technology. Other applications include growth hormone, vaccines, and diagnostic reagents. (fda.gov)
Biosafety and oversight
Early experiments prompted questions about the consequences of introducing unfamiliar genetic combinations into organisms. The February 1975 Asilomar conference recommended that selected experiments proceed under containment guidelines rather than an indefinite moratorium. The United States National Institutes of Health issued its first recombinant DNA research guidelines in 1976. (pmc.ncbi.nlm.nih.gov)
Oversight considers the host, vector, inserted sequences, and experimental activity rather than treating all recombinant constructs as equivalent hazards. NIH guidelines specify responsibilities for institutions and institutional biosafety committees, including assessment of applicable experiments and containment requirements. Their scope includes recombinant and synthetic nucleic-acid research, with different review provisions and exemptions for different categories of work. (osp.od.nih.gov)